CO4950553A1 - Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion - Google Patents
Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacionInfo
- Publication number
- CO4950553A1 CO4950553A1 CO98015157A CO98015157A CO4950553A1 CO 4950553 A1 CO4950553 A1 CO 4950553A1 CO 98015157 A CO98015157 A CO 98015157A CO 98015157 A CO98015157 A CO 98015157A CO 4950553 A1 CO4950553 A1 CO 4950553A1
- Authority
- CO
- Colombia
- Prior art keywords
- 4alkyl
- cycloalkyl
- hydrogen
- isoquinolin
- benzamide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9705619.6A GB9705619D0 (en) | 1997-03-18 | 1997-03-18 | Novel compounds |
GBGB9726695.1A GB9726695D0 (en) | 1997-12-17 | 1997-12-17 | Novel compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO4950553A1 true CO4950553A1 (es) | 2000-09-01 |
Family
ID=26311215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO98015157A CO4950553A1 (es) | 1997-03-18 | 1998-03-18 | Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0968190A1 (tr) |
JP (1) | JP3690423B2 (tr) |
KR (1) | KR100568654B1 (tr) |
CN (1) | CN1183116C (tr) |
AR (1) | AR012092A1 (tr) |
AU (1) | AU737955B2 (tr) |
BR (1) | BR9809047A (tr) |
CA (1) | CA2284218A1 (tr) |
CO (1) | CO4950553A1 (tr) |
IL (1) | IL131756A0 (tr) |
NO (1) | NO314081B1 (tr) |
NZ (1) | NZ337424A (tr) |
PL (1) | PL192116B1 (tr) |
TR (1) | TR199902283T2 (tr) |
TW (1) | TW555694B (tr) |
WO (1) | WO1998041508A1 (tr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9726695D0 (en) * | 1997-12-17 | 1998-02-18 | Smithkline Beecham Plc | Novel compounds |
WO1999021836A1 (en) * | 1997-10-24 | 1999-05-06 | Smithkline Beecham Plc | Substituted isoquinoline derivatives and their use as anticonvulsants |
GB9817424D0 (en) | 1998-08-11 | 1998-10-07 | Smithkline Beecham Plc | Novel compounds |
US20020006908A1 (en) * | 1998-12-03 | 2002-01-17 | Daniel P. Van Kammen | Anticonvulsant derivatives useful in treating schizophrenia |
EP1177188B1 (en) * | 1999-05-12 | 2005-10-12 | Ortho-McNeil Pharmaceutical, Inc. | Pyrazole carboxamides useful for the treatment of obesity and other disorders |
GB9915589D0 (en) * | 1999-07-02 | 1999-09-01 | Smithkline Beecham Plc | Novel compounds |
FR2795724B1 (fr) * | 1999-07-02 | 2002-12-13 | Sanofi Synthelabo | Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant |
EP2033953A1 (en) * | 2002-02-15 | 2009-03-11 | Glaxo Group Limited | Vanilloid receptor modulators |
GB0210762D0 (en) * | 2002-05-10 | 2002-06-19 | Glaxo Group Ltd | Compounds |
WO2004014388A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors |
GB0226724D0 (en) * | 2002-11-15 | 2002-12-24 | Merck Sharp & Dohme | Therapeutic agents |
MXPA05013434A (es) | 2003-06-12 | 2006-03-17 | Astellas Pharma Inc | Derivados de benzamida o sal del mismo. |
GB2406856B (en) * | 2003-10-07 | 2005-10-19 | Renovis Inc | Amide compounds as ion channel ligands and uses thereof |
GB2413129A (en) * | 2003-10-07 | 2005-10-19 | Renovis Inc | Aromatic amide compounds as ion channel ligands and uses thereof |
CA2553968A1 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain |
JP2008513426A (ja) * | 2004-09-20 | 2008-05-01 | バイオリポックス エービー | 炎症の治療に有用なピラゾール化合物 |
SE0403117D0 (sv) * | 2004-12-21 | 2004-12-21 | Astrazeneca Ab | New compounds 1 |
DK2046787T3 (da) | 2006-08-01 | 2011-07-18 | Glaxo Group Ltd | Pyrazolo[3,4-B]pyridin-forbindelser, og deres anvendelse som PDE4-inhibitorer |
CN106608901B (zh) * | 2015-10-22 | 2020-10-16 | 彭莉 | 二羟基二甲基四氢异喹啉-3-甲酰-Lys(Lys-Ala),其合成,活性及应用 |
CN111138359A (zh) * | 2020-01-19 | 2020-05-12 | 浙江农林大学暨阳学院 | 制备3-羰基-4-叠氮基-n-苯磺酰基-1,2,3,4-四氢异喹啉类化合物的方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
PL330465A1 (en) * | 1996-06-17 | 1999-05-24 | Smithkline Beecham Plc | Substituted benzamide derivatives and their application as anticonvulsants |
-
1998
- 1998-03-16 BR BR9809047-0A patent/BR9809047A/pt not_active Application Discontinuation
- 1998-03-16 JP JP54024898A patent/JP3690423B2/ja not_active Expired - Fee Related
- 1998-03-16 WO PCT/GB1998/000782 patent/WO1998041508A1/en not_active Application Discontinuation
- 1998-03-16 NZ NZ337424A patent/NZ337424A/en unknown
- 1998-03-16 AU AU64128/98A patent/AU737955B2/en not_active Ceased
- 1998-03-16 CN CNB988048809A patent/CN1183116C/zh not_active Expired - Fee Related
- 1998-03-16 CA CA002284218A patent/CA2284218A1/en not_active Abandoned
- 1998-03-16 KR KR1019997008443A patent/KR100568654B1/ko not_active IP Right Cessation
- 1998-03-16 TR TR1999/02283T patent/TR199902283T2/tr unknown
- 1998-03-16 PL PL335676A patent/PL192116B1/pl unknown
- 1998-03-16 IL IL13175698A patent/IL131756A0/xx active IP Right Grant
- 1998-03-16 EP EP98909647A patent/EP0968190A1/en not_active Withdrawn
- 1998-03-17 AR ARP980101199A patent/AR012092A1/es unknown
- 1998-03-18 CO CO98015157A patent/CO4950553A1/es unknown
- 1998-03-20 TW TW087104135A patent/TW555694B/zh not_active IP Right Cessation
-
1999
- 1999-09-17 NO NO19994510A patent/NO314081B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
KR20000076342A (ko) | 2000-12-26 |
TW555694B (en) | 2003-10-01 |
PL335676A1 (en) | 2000-05-08 |
IL131756A0 (en) | 2001-03-19 |
AU737955B2 (en) | 2001-09-06 |
KR100568654B1 (ko) | 2006-04-07 |
EP0968190A1 (en) | 2000-01-05 |
JP2001515504A (ja) | 2001-09-18 |
CN1255124A (zh) | 2000-05-31 |
JP3690423B2 (ja) | 2005-08-31 |
BR9809047A (pt) | 2000-08-01 |
AU6412898A (en) | 1998-10-12 |
WO1998041508A1 (en) | 1998-09-24 |
CN1183116C (zh) | 2005-01-05 |
NZ337424A (en) | 2001-08-31 |
PL192116B1 (pl) | 2006-08-31 |
NO994510L (no) | 1999-09-17 |
NO314081B1 (no) | 2003-01-27 |
NO994510D0 (no) | 1999-09-17 |
TR199902283T2 (tr) | 1999-12-21 |
CA2284218A1 (en) | 1998-09-24 |
AR012092A1 (es) | 2000-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO4950553A1 (es) | Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion | |
SE9203825L (sv) | Dubbelt verkande inhibitorer foer no-syntas och cyklooxygenas, foerfarande foer framstaellning daerav och terapeutiska kompositioner innehaallande desamma | |
ATE297203T1 (de) | Antithrombotische mitteln | |
TR200201874T2 (tr) | Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler. | |
EA200000920A1 (ru) | Производные бициклических гидроксамовых кислот | |
EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
SE0101579D0 (sv) | New compounds | |
HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
SV2002000244A (es) | Metodos y compuestos para inhibir mrp1 ref.x-13353 | |
CO4950515A1 (es) | Nuevos derivados de la quinolina para uso medicinal | |
AR029343A1 (es) | USO DE UN ANTAGONISTA DE NMDA DE BAJA AFINIDAD PARA EL TRATAMIENTO DE LA DEPRESIoN | |
DE60121587D1 (de) | Zyklische gmp-spezifische phosphodiesteraseinhibitoren | |
HUP0105201A2 (hu) | Férfiklimax kezelése ösztrogén agonistákat/antagonistákat és tesztoszteront tartalmazó gyógyászati készítmények alkalmazásával | |
DE60014343D1 (de) | N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten | |
SE8802412L (sv) | Tiokarbamidderivat | |
NZ504706A (en) | Substituted isoquinoline derivatives and their use as anticonvulsants | |
BR0211425A (pt) | Método para a preparação de compostos, e, uso de uma composição | |
ATE286395T1 (de) | Antithrombotische mittel | |
CO5200763A1 (es) | Compuestos de carboxamida con actividad anticonvulsionante y su preparacion | |
CO5040081A1 (es) | Nuevos compuestos vidad farmaaceutica | |
CO4950554A1 (es) | Derivados de 1,3-dihidro o 3,4-dihidroisoquinolin-benzamida | |
CO4750824A1 (es) | Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n | |
CO4700450A1 (es) | Nuevos azepanos y homologos de su anillo | |
DE60122350D1 (de) | Benzoesaüre derivate und deren verwendung | |
AR013004A1 (es) | Derivados de aminospiropiperidina quinazolina, composicion farmaceutica, uso de dichos derivados en la preparacion de medicamentos, proceso para lapreparacion de dichos derivados y compuestos intermediarios para su exclusivo uso en dicho proceso. |